NCT01413165: Phase 4, Open Label, Multicentre, 2 Year Safety Study of Lisdexamfetamine Dimesylate in Children/Adolescents With ADHD |
|
|
| Not yet recruiting | 4 | 12 | Europe | Lisdexamfetamine dimesylate, SPD 489 | Maastricht University Medical Center, Shire Development LLC | Attention Deficit Disorder With Hyperactivity | 08/13 | 12/13 | | |
